Use the pattern recognition workspace to apply Stalled Pattern recognition and other studies to Can Fite. It emphasizes pattern recognition signals tied to momentum and continuation while keeping volatility, risk, and performance context in view.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twelve with a total number of output elements of forty-nine. The function did not return any valid pattern recognition events for the selected time horizon. The Stalled pattern represents a weakness and consolidation and Can Fite Biopharma possible reversal in trend.
Can Fite Technical Analysis Modules
Most technical analysis of Can Fite help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Can from various momentum indicators to cycle indicators. When you analyze Can charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel. Can-Fite Biopharma operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 8 people. The stock overview for Can Fite summarizes business drivers, financial profile, and market behavior. The company is positioned within Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Current metrics include P/B of 1.28. Can Fite has market cap of 15.24 M, ROE of -2.64%.
Methodology
Unless otherwise specified, financial data for Can Fite Biopharma is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Can (USA Stocks:CANF) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Can Fite Biopharma is covered by 2 analysts. 1 analyst has submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include J.P. Morgan, Guggenheim Securities, Bank of America Securities, Oppenheimer & Co., Evercore ISI, among others. Updates may occur throughout the day.
Align your values with your investing style
Using Can Fite Biopharma inside a theme workflow gives investors a structured way to compare related stocks, funds, ETFs, and crypto assets before allocating capital. The practical benefit is that the selected idea can be tuned either for higher upside or for tighter risk control.
Thematic Opportunities
Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
A comprehensive view of Can Fite Biopharma starts with financial statements and ratio context. Financial ratios provide context for profitability, efficiency, and growth trends. Outlined below are key reports that provide context for Can Fite Biopharma Stock:
Can Fite has market cap of 15.24 M, operating margin of -24.25%, ROE of -2.64%. See Trending Equities for portfolio-level analysis. This suggests a position in Can Fite Biopharma within the portfolio mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.
Analysis related to Can Fite should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Quarterly Revenue Growth
-0.36
Return On Assets
-0.82
Return On Equity
-2.64
Understanding Can Fite Biopharma includes distinguishing between market value and book value, where book value reflects Can accounting equity. Can Fite's market capitalization is 15.24 M. A P/B ratio of 1.28 indicates the market values Can Fite above its accounting book value. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
The concept of value for Can Fite differs from its quoted price, since each reflects a different lens. For Can Fite, key inputs include a P/B ratio of 1.28, ROE of -2.64%, and revenue of 674 K. Trading price represents the transaction level agreed by market participants.
